Indian stocks: Visit www.stage2stocks.com →

Novavax, Inc.

Stage 2 · Advancing · week 5

As of Oct 22, 2026, Novavax is in Stage 2, the uptrend phase, now in week 5 (since Sep 24, 2026). It closed at $9.99, 22.1% below its 52-week high and above its 200-day average, which is rising.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. More about the company

$9.99
-9.26% today
$1.6B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is NVAX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 24w
S3 16w
S4 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 6w → S4 24w → S1 9w → S2 12w → S3 16w → S4 10w → S1 2w → S4 17w → S1 11w → S2 9w → S3 6w → S4 5w → S1 1w → S2 11w → S3 8w → S2 6w → S3 4w → S4 1w → S3 1w → S1 2w → S2 4w current
Total tracked: 166 weeks across 21 stage runs.

NVAX among Biotechnology143rd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…143NVAXStage 2 · wk 567−5.3%
vs 52W High
-22.1%
$6.22 lo$12.82 hi
22.1% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 5
1w13w26w
Week 5, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
8.2%
200 DMA: $9.23 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.80x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-5.3%
3M
+33.9%
6M
+22.6%
YTD
+40.1%
1Y
+16.3%
Scan Membership
Breakout Watch
Latest: 2024-05-22
6 appearances in last 60 days. First seen: 2018-11-05.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 5 · Vol 1.80x
2026-10-21S2
Wk 4 · Vol 0.81x
2026-10-20S2
Wk 4 · Vol 0.98x
2026-10-19S2
Wk 4 · Vol 0.93x
2026-10-16S2
Wk 4 · Vol 1.51x
2026-10-15S2
Wk 4 · Vol 1.14x
2026-10-14S2
Wk 3 · Vol 1.34x
2026-10-13S2
Wk 3 · Vol 1.34x
2026-10-12S2
Wk 3 · Vol 1.38x
2026-10-09S2
Wk 3 · Vol 3.26x
2026-10-08S2
Wk 3 · Vol 1.08x
2026-10-07S2
Wk 2 · Vol 1.49x
Moving averages & range
50 DMA
$10.25
200 DMA
$9.23
52W High
$12.82
52W Low
$6.22
5D Low
$9.99
Resistance levels (recent highs)
20d High
$12.82
60d High
$12.82
120d High
$12.82
250d High
$12.82
Next resistance
+28.3%
to 20d High
Dividend Yield
0.00%
P/B -8.6

Novavax: quick answers

What stage is Novavax in?

As of Oct 22, 2026, Novavax (NVAX) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 24, 2026 and is in week 5. What the four stages mean

Is Novavax in an uptrend?

Yes. Novavax is in a Stage 2 uptrend. It trades 8.2% above its 200-day average, which is rising.

How far is Novavax from its 52-week high?

Novavax closed at $9.99 on Oct 22, 2026, 22.1% below its 52-week high of $12.82. Its 52-week low is $6.22.

How has Novavax performed over the past year?

As of Oct 22, 2026, Novavax is up 16.3% over the past year and up 40.1% so far in 2026.

Which sector and industry is Novavax in?

Novavax is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.